Core Insights - Visionary Holdings Inc. has appointed Ms. Wenxuan Cai as the CEO of its subsidiary, Visionary Health Technology Group Limited in Hong Kong, effective immediately [1] - The company has established a new wholly owned subsidiary in Nanjing, China, focusing on sales execution and market development, marking a shift from strategic positioning to active revenue generation [2] Leadership and Market Strategy - Ms. Cai brings nearly two decades of experience in market expansion and sales organization building, particularly in the healthcare sector, and will focus on enhancing sales infrastructure and execution [3][8] - The Nanjing entity will serve as a frontline commercial platform for regional sales operations, completing a fully integrated commercial structure alongside the Hong Kong platform [4] Commercialization Efforts - The company has transitioned from conceptual planning to operational commercialization, with a strong emphasis on building high-performance sales teams and translating market strategies into commercial results [5][6] - Recent milestones include strategic entry into cellular rejuvenation and aesthetic treatment markets, completion of global technology licensing, and the launch of a diversified product portfolio [9] Growth Potential - With leadership, products, and sales infrastructure aligned, the company is well-positioned to capitalize on the growing demand for advanced cellular-based and aesthetic solutions across Asia [7]

Core Viewpoint - BioHarvest Sciences Inc. is set to release its financial results for the second quarter of 2025 on August 11, 2025, before market opening, and will host an investor conference call to discuss these results and provide a corporate update [1][2]. Company Overview - BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology platform to cultivate plant-based compounds without the need for the actual plants [4]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) for clients seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements [4]. Conference Call Details - The investor conference call will take place on August 11, 2025, at 8:00 a.m. Eastern Time, with dial-in options provided for U.S./Canada and international participants [2]. - A playback of the call will be available until August 25, 2025, with specific numbers provided for accessing the playback [3].

Core Insights - BioHarvest Sciences Inc. has been invited to present at the Canaccord Genuity 45th Annual Growth Conference scheduled for August 12-14, 2025, in Boston, Massachusetts [1] - CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and will present the company's growth plans during the conference [2][3] - The company is focused on building momentum in both its consumer and contract development and manufacturing organization (CDMO) businesses, aiming to scale operations effectively [3] Company Overview - BioHarvest Sciences Inc. specializes in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need for growing the actual plants [4] - The company operates in two main business verticals: as a CDMO for clients seeking novel plant-based compounds and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements [4]